UNASSIGNED:本研究的目的是在接受阿片类激动剂治疗(OAT)的患者人群中测量处方口服兴奋剂与可卡因消费的相关性。
UNASSIGNED:该研究是一项回顾性临床队列研究,使用2014年4月至2021年2月在安大略省加拿大成瘾治疗中心(CATC)内就诊的所有接受OAT的患者的医疗记录。线性混合效应模型适用于处方口服兴奋剂的暴露,以及尿液分析药物对可卡因的阳性筛查结果。年龄的协变量,性别,对患者的随机效应进行了拟合,以解释患者观察之间和内部随时间的差异.
UNASSIGNED:在接受OAT治疗的患者中,n=314名患者服用了口服兴奋剂,n=11,879名患者在安大略省CATC诊所(n=92,n=145名医生)中没有服用口服兴奋剂,接受口服兴奋剂患者的入组平均年龄为37.0,SD=8.8,其中43.6%为女性患者,未接受口服兴奋剂患者的入组平均年龄为36.6,SD=10.7,其中39.6%为女性患者.线性混合效应模型显示,随着时间的推移,固定效应B=0.001的可卡因阳性尿检没有差异,然而,当考虑固定效应之间的类间相关系数(ICC)时,我们发现,在可卡因尿检阳性时,口服兴奋剂处方后的时间与ICC降低相关=-0.14.处方ICC=-0.92和男性ICC=-0.23的年龄增加与可卡因阳性尿液减少有关。
UASSIGNED:使用口服兴奋剂处方来治疗可卡因的使用在现实世界中没有临床上显著的益处。与没有口服兴奋剂处方的患者相比,接受口服兴奋剂处方的患者在治疗前后消耗更多的可卡因。我们还观察到,自治疗开始以来,可卡因的使用随着时间的增加而减少。
UNASSIGNED: The objective of this study was to measure the association of prescribed oral stimulants with the consumption of cocaine among a population of patients receiving Opioid Agonist Therapy (OAT).
UNASSIGNED: The study was a retrospective clinical cohort study using the medical records of all patients receiving OAT who attended treatment clinics within the Canadian Addiction Treatment Centers (CATC) in Ontario from April 2014 to February 2021. Linear mixed-effects models were fit for the exposure of prescribed oral stimulants, and the outcome of a positive urinalysis drug screen for cocaine. Covariates for age, sex, and a random effect for patients were fitted to account for differences between and within patient observations over time.
UNASSIGNED: Among patients receiving OAT therapy n = 314 patients were prescribed oral stimulants and n = 11,879 patients were not prescribed oral stimulants among Ontario CATC clinics (n = 92, n = 145 physicians), the mean age at enrollment for patients receiving oral stimulants was 37.0, SD = 8.8, with 43.6% female patients and for patients not receiving oral stimulants mean age was 36.6, SD = 10.7, with 39.6% female patients. Linear mixed effects models showed no difference in cocaine-positive urine tests over time for fixed effects B = 0.001, however, when considering the Interclass correlation coefficient (ICC) between the fixed effects, we found that time since the prescription of an oral stimulant was associated with a decrease of ICC = -0.14 in cocaine positive urine tests. Increasing age at prescription ICC = -0.92, and being male ICC = -0.23 were associated with decreasing cocaine-positive urine.
UNASSIGNED: The use of oral stimulant prescriptions to treat cocaine use had no clinically significant benefit in a real-world setting. Patients who receive prescriptions for oral stimulants consume more cocaine before and after treatment compared to patients without an oral stimulant prescription. We also observed that cocaine use was reduced with increased time since treatment initiation.